Mapping the heparin-binding site of the BMP antagonist gremlin by site-directed mutagenesis based on predictive modelling

Biochemical Journal

Volumn 470, Issue 1, 2015, Pages 53-64

  Tatsinkam, Arnold ^a   Mulloy, Barbara ^a   Rider, Christopher C ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Bone morphogenetic protein; Bone morphogenetic protein antagonist; CAN family; Gremlin; Heparan sulfate; Heparin

Indexed keywords

ARGININE; BONE MORPHOGENETIC PROTEIN 4; CYTOKINE RECEPTOR ANTAGONIST; GLUTARALDEHYDE; GLYCOPROTEIN; GREMLIN PROTEIN; HEPARIN; LYSINE; MUTANT PROTEIN; MYC PROTEIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG; BMP4 PROTEIN, HUMAN; CKTSF1B1 PROTEIN, MOUSE; SIGNAL PEPTIDE;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; COMPUTER PREDICTION; CONTROLLED STUDY; CROSS LINKING; DIMERIZATION; ELUTION; GENE MAPPING; HUMAN; MOLECULAR INTERACTION; MOLECULAR MODEL; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHO CELL LINE; CRICETULUS; FORECASTING; GENETICS; HAMSTER; METABOLISM; MOLECULAR GENETICS; MOUSE; PHYSIOLOGY; PROCEDURES; PROTEIN SECONDARY STRUCTURE;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; BONE MORPHOGENETIC PROTEIN 4; CHO CELLS; CRICETINAE; CRICETULUS; FORECASTING; HEPARIN; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN STRUCTURE, SECONDARY;

EID: 84938815274     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20150228     Document Type: Article

References (49)

1. Rider, C.C. and Mulloy, B. (2010) Bone morphogenetic proteins and growth differentiation factor cytokine families and their protein antagonists. Biochem. J. 429, 1-12 CrossRef PubMed
2. Rider, C.C. (2006) Heparin/heparan sulphate binding in the TGF-β cytokine superfamily. Biochem. Soc. Trans. 34, 458-460 CrossRef PubMed
3. Avsian-Kretchmer, O. and Hsueh, A.J. (2004) Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists. Mol. Endocrinol. 18, 1-12CrossRef PubMed
4. Winkler, D.G., Sutherland, M.K., Geoghegan, J.C., Yu, C., Hayes, T., Skonier, J.E., Shpektor, D., Jonas, M., Kovacevich, B.R., Staehling-Hampton, K. et al. (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 22, 6267-6276 CrossRef PubMed
5. Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S.E. and Wu, D. (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 280, 19883-19887 CrossRef PubMed
6. Itasaki, N., Jones, C.M., Mercurio, S., Rowe, A., Domingos, P.M., Smith, J.C. and Krumlauf, R. (2003) Wise, a context-dependent activator and inhibitor of Wnt signalling. Development 130, 4295-4305 CrossRef PubMed
7. Gao, H., Chakraborty, G., Lee-Lim, A.P., Mo, Q., Decker, M., Vonica, A., Shen, R., Brogi, E., Brivanlou, A.H. and Giancotti, A.H. (2012) The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 150, 764-779 CrossRef PubMed
8. Chiodelli, P., Mitola, S., Ravelli, C., Oreste, P., Rusnati, M. and Presta, M. (2011) Heparan sulfate proteoglycans mediate the angiogenic activity of the vascular endothelial growth factor receptor-2 agonist gremlin. Arterioscler. Thromb. Vasc. Biol. 31, e116-e127 CrossRef PubMed
9. Veverka, V., Henry, A.J., Slocombe, P.M., Ventom, A., Mulloy, B., Muskett, F.W., Muzylak, M., Greenslade, K., Moore, A., Zhang, L. et al. (2009) Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J. Biol. Chem. 284, 10890-10900 CrossRef PubMed
10. Lintern, K.B., Guidato, S., Rowe, A., Saldanha, J.W. and Itasaki, N. (2009) Characterization of wise protein and its molecular mechanism to interact with both Wnt and BMP signals. J. Biol. Chem. 284, 23159-23168 CrossRef PubMed
11. Nolan, K., Kattamuri, C., Luedeke, D.M., Deng, X., Jagpal, A., Zhang, F., Linhardt, R.J., Kenny, A.P., Zorn, A.M. and Thompson, T.B. (2013) Structure of protein related to Dan and Cerberus: insights into the mechanism of bone morphogenetic protein antagonism. Structure 21, 1417-1429 CrossRef PubMed
12. Topol, L.Z., Bardot, B., Zhang, Q., Resau, J., Huillard, E., Marx, M., Calothy, G. and Blair, D.G. (2000) Biosynthesis, post-translation modification, and functional characterisation of Drm/gremlin. J. Biol. Chem. 275, 8785-8793 CrossRef PubMed
13. Sudo, S., Avsian-Kretchmer, O., Wang, L.S. and Hsueh, A.J. (2004) Protein related to DAN and cerberus is a bone morphogenetic protein antagonist that participates in ovarian paracrine regulation. J. Biol. Chem. 279, 23134-23141 CrossRef PubMed
14. Church, R.H., Krishnakumar, A., Urbanek, A., Geschwindner, S., Meneely, J., Bianchi, A., Basta, B., Monaghan, S., Elliott, C., Stromstedt, M. et al. (2015) Gremlin1 preferentially binds to bone morphogenetic protein-2 (BMP-2) and BMP-4 over BMP-7. Biochem. J. 466, 55-68 PubMed
15. Mitola, S., Ravelli, C., Moroni, E., Salvi, V., Leali, D., Ballmer-Hofer, K., Zammataro, L. and Presta, M. (2010) Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. Blood 116, 3677-3680 CrossRef PubMed
16. Khokha, M.K., Hsu, D., Brunet, L.J., Dionne, M.S. and Harland, R.M. (2003) Gremlin is the BMP antagonist required for maintenance of Shh and Fgf signals during limb patterning. Nat. Genet. 34, 303-307 CrossRef PubMed
17. Michos, O., Panman, L., Vintersten, K., Beier, K., Zeller, R. and Zuniga, A. (2004) Gremlin-mediated BMP antagonism induces the epithelial-mesenchymal feedback signaling controlling metanephric kidney and limb organogenesis. Development 131, 3401-3410 CrossRef PubMed
18. Canalis, E., Parker, K. and Zanotti, S. (2012) Gremlin 1 is required for skeletal development and postnatal skeletal homeostasis. J. Cell. Physiol. 227, 269-277 CrossRef PubMed
19. Gazzerro, E., Pereira, R.C., Jorgetti, V., Olson, S., Economides, A.N. and Canalis, E. (2005) Skeletal overexpression of gremlin impairs bone formation and causes osteopenia. Endocrinology 146, 655-665 CrossRef PubMed
20. Gazzerro, E., Smerdel-Ramoya, A., Zanotti, S., Stadmeyer, L., Durant, D., Economides, A.N. and Canalis, E. (2007) Conditional deletion of gremlin causes a transient increase in bone formation and bone mass. J. Biol. Chem. 282, 31549-31557 CrossRef PubMed
21. Roxburgh, S.A., Murphy, M., Pollock, C.A. and Brazil, D.P. (2006) Recapitulation of embryological programmes in renal fibrosis - the importance of epithelial cell plasticity and developmental genes. Nephron Physiol. 103, 139-148 CrossRef
22. Koli, K., Myllarniemi, M., Vuorinen, K., Salmenkivi, K., Ryynanen, M.J., Kinnula, V.L. and Keski-Oja, J. (2006) Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis. Am. J. Pathol. 169, 61-71 CrossRef PubMed
23. Boers, W., Aarrass, S., Linthorst, C., Pinzani, M., Elferink, R.O. and Bosma, P. (2006) Transcriptional profiling reveals novel markers of liver fibrogenesis: gremlin and insulin-like growth factor-binding proteins. J. Biol. Chem. 281, 16289-16295 CrossRef PubMed
24. Lee, H., O'Meara, S.J., O'Brien, C. and Kane, R. (2007) The role of gremlin, a BMP antagonist, and epithelial-to-mesenchymal transition in proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 48, 4291-4299 CrossRef PubMed
25. Wordinger, R.J., Fleenor, D.L., Hellberg, P.E., Pang, I.H., Tovar, T.O., Zode, G.S., Fuller, J.A. and Clark, A.F. (2007) Effects of TGF-beta2, BMP-4, and gremlin in the trabecular meshwork: implications for glaucoma. Invest. Ophthalmol. Vis. Sci. 48, 1191-1200 CrossRef PubMed
26. Mueller, K.A., Tavlaki, E., Schneider, M., Jorbenadze, R., Geisler, T., Kandolf, R., Gawaz, M., Mueller, I.I. and Zuern, C.S. (2013) Gremlin-1 identifies fibrosis and predicts adverse outcome in patients with heart failure undergoing endomyocardial biopsy. J. Cardiac Failure 19, 678-684 CrossRef
27. Roxburgh, S.A., Kattla, J.J., Curran, S.P., O'Meara, Y.M., Pollock, C.A., Goldschmeding, R., Godson, C., Martin, F. and Brazil, D.P. (2009) Allelic depletion of grem1 attenuates diabetic kidney disease. Diabetes 58, 1641-1650 CrossRef PubMed
28. Zhang, Q., Shi, Y., Wada, J., Malakauskas, S.M., Liu, M., Ren, Y., Du, C., Duan, H., Li, Y, Li, Y. and Zhang, Y. (2013) In vivo delivery of gremlin siRNA plasmid reveals therapeutic potential against diabetic nephropathy by recovering bone morphogenetic protein-7. PLoS One 5, e11709 CrossRef PubMed
29. Huang, H., Huang, H., Li, Y., Liu, M., Shi, Y., Chi, Y. and Zhang, T. (2013) Gremlin induces cell proliferation and extracellular matrix accumulation in mouse mesangial cells exposed to high glucose via the ERK1/2 pathway. BMS Nephrol. 14, 33 CrossRef PubMed
30. Li, G., Li, Y., Liu, S., Chi, Y., Liu, G. and Shan, T. (2013) Gremlin aggravates hyperglycemia-induced podocyte injury by a TGFβ/smad dependent signaling pathway. J. Cell. Biochem. 114, 2101-2113 CrossRef PubMed
31. Sneddon, J.B., Zhen, H.H., Montgomery, K., van de Rijn, M., Tward, A.D., West, R., Gladstone, H., Chang, H.Y., Morganroth, G.S., Oro, A.E. and Brown, P.O. (2006) Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 103, 14842-14847 CrossRef PubMed
32. Mulvihill, M.S., Kwon, Y. W, Lee, S., Fang, L.T., Choi, H., Ray, R., Kang, H.C., Mao, J.H., Jablons, D. and Kim, I.J. (2012) Gremlin is overexpressed in lung adenocarcinoma and increases cell growth and proliferation in normal lung cells. PLoS One 7, e42264 CrossRef PubMed
33. Karagiannis, G.S., Berk, A., Dimitromanolakis, A. and Diamandis, E.P. (2013) Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1. Mol. Oncol. 7, 826-839 CrossRef PubMed
34. Kattamuri, C., Luedeke, D.M., Nolan, K., Rankin, S.A., Greis, K.D., Zorn, A.M. and Thompson, T.B. (2012) Members of the DAN family are BMP antagonists that form highly stable noncovalent dimers. J. Mol. Biol. 424, 313-327 CrossRef PubMed
35. Najjam, S., Gibbs, R.V., Gordon, M.Y. and Rider, C.C. (1997) Characterisation of human recombinant interleukin 2 binding to heparin and heparan sulphate using an ELISA approach. Cytokine 9, 1013-1022 CrossRef PubMed
36. Alfano, I., Vora, P., Mummery, R.S., Mulloy, B. and Rider, C.C. (2007) The major determinant of the heparin binding of glial cell-line derived neurotrophic factor is near the aminoterminus and is dispensable for receptor binding. Biochem. J. 404, 131-140 CrossRef PubMed
37. Higuchi, R., Krummel, B. and Saiki, R.K. (1988) A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Res. 16, 7351-7367 CrossRef PubMed
38. Ho, S.N., Hunt, H.D., Horton, R.M., Pullen, J.K. and Pease, L.R. (1989) Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77, 51-59 CrossRef PubMed
39. Ke, S.H. and Madison, E.L. (1997) Rapid and efficient site-directed mutagenesis by single-tube 'megaprimer' PCR method. Nucleic Acids Res. 25, 3371-3372 CrossRef PubMed
40. Urban, A., Neukirchen, S. and Jaeger, K.E. (1997) A rapid and efficient method for site-directed mutagenesis using one-step overlap extension PCR. Nucleic Acids Res. 25, 2227-2228 CrossRef PubMed
41. Stabile, H., Mitola, S., Moroni, E., Belleri, M., Nicoli, S., Coltrini, D., Peri, F., Pessi, A., Orsatti, L., Talamo, F. et al. (2007) Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood 109, 1834-1840 CrossRef PubMed
42. Mulloy, B. and Forster, M.J. (2008) Application of drug discovery software to the identification of heparin-binding sites on protein surfaces: a computational survey of the 4-helix cytokines. Mol. Simulation 34, 481-489 CrossRef
43. Biasini, M., Bienert, S., Waterhouse, A., Arnold, K., Studer, G., Schmidt, T., Kiefer, F., Cassarino, T.G., Bertoni, M., Bordoli, L. and Schwede, T. (2014) SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res 42, W252-W258 CrossRef PubMed
44. Ohkawara, B., Iemura, S., ten Dijke, P. and Ueno, N. (2002) Action range of BMP is defined by its N-terminal basic amino acid core. Curr. Biol. 12, 205-209 CrossRef PubMed
45. Hinck, A.P. and Huang, T. (2013) TGF-β antagonists: same knot, but different hold. Structure 21, 1269-1270 CrossRef PubMed
46. Lau, E.K., Paavola, C.D., Johnson, Z., Gaudry, J.P., Geretti, E., Borlat, F., Kungl, A.J., Proudfoot, A.E. and Handel, T.M. (2004) Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo. J.Biol. Chem. 279, 22294-22305 CrossRef PubMed
47. Nolan, K., Kattamuri, C., Luedeke, D.M., Angerman, E.B., Rankin, S.A., Stevens, M.L., Zorn, A.M. and Thompson, T.B. (2015) Structure of neuroblastoma suppressor of tumorigenicity 1 (NBL1): insights for the functional variability across bone morphogenetic protein (BMP) antagonists. J. Biol. Chem. 290, 4759-4771 PubMed
48. Kowanetz, M. and Ferrara, N. (2006) Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res. 12, 5018-5022 CrossRef PubMed
49. Paine-Saunders, S., Viviano, B.L., Economides, A.N. and Saunders, S. (2002) Heparan sulfate proteoglycans retain Noggin at the cell surface: a potential mechanism for shaping bone morphogenetic protein gradients. J. Biol. Chem. 277, 2089-2096 CrossRef PubMed